‘We’re trying to do the right thing.’ GSK sets diversity targets, partners with DEI firm to educate trial staff

Fierce Biotech May 22, 2024
Helen Floersh

GSK is doubling down on its efforts to make clinical trials more diverse, starting with defined enrollment targets and training its clinical R&D workforce on issues around diversity, equity, inclusion and bias in healthcare.

The pharma giant announced in early May that it had partnered with Blue Level Training to provide educational materials to the roughly 10,000 principal investigators and staff who have face-to-face interactions with patients in clinical trials. The Blue Level partnership followed news that the company is aiming to have enrollment for at least half of all phase 3 trials in 2024 reflect the populations most impacted by the disease the tested therapy is designed to treat.

Until now, most pharmas—including GSK—have relied on hindsight...

Today's Sponsors

Today's Sponsor